JP2012507020A5 - - Google Patents

Download PDF

Info

Publication number
JP2012507020A5
JP2012507020A5 JP2011533626A JP2011533626A JP2012507020A5 JP 2012507020 A5 JP2012507020 A5 JP 2012507020A5 JP 2011533626 A JP2011533626 A JP 2011533626A JP 2011533626 A JP2011533626 A JP 2011533626A JP 2012507020 A5 JP2012507020 A5 JP 2012507020A5
Authority
JP
Japan
Prior art keywords
subject
assay
fragment
metabolic syndrome
copeptin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011533626A
Other languages
English (en)
Japanese (ja)
Other versions
JP5785086B2 (ja
JP2012507020A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/007923 external-priority patent/WO2010049179A1/en
Publication of JP2012507020A publication Critical patent/JP2012507020A/ja
Publication of JP2012507020A5 publication Critical patent/JP2012507020A5/ja
Application granted granted Critical
Publication of JP5785086B2 publication Critical patent/JP5785086B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011533626A 2008-10-31 2009-10-29 糖尿病の予測バイオマーカーとしてのアルギニンバソプレシンプロホルモン Active JP5785086B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08168096.9 2008-10-31
EP08168096 2008-10-31
PCT/EP2009/007923 WO2010049179A1 (en) 2008-10-31 2009-10-29 Arginine vasopressin pro-hormone as predictive biomarker for diabetes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015042777A Division JP6055005B2 (ja) 2008-10-31 2015-03-04 糖尿病の予測バイオマーカーとしてのアルギニンバソプレシンプロホルモン

Publications (3)

Publication Number Publication Date
JP2012507020A JP2012507020A (ja) 2012-03-22
JP2012507020A5 true JP2012507020A5 (enExample) 2012-12-06
JP5785086B2 JP5785086B2 (ja) 2015-09-24

Family

ID=40445457

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011533626A Active JP5785086B2 (ja) 2008-10-31 2009-10-29 糖尿病の予測バイオマーカーとしてのアルギニンバソプレシンプロホルモン
JP2015042777A Active JP6055005B2 (ja) 2008-10-31 2015-03-04 糖尿病の予測バイオマーカーとしてのアルギニンバソプレシンプロホルモン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015042777A Active JP6055005B2 (ja) 2008-10-31 2015-03-04 糖尿病の予測バイオマーカーとしてのアルギニンバソプレシンプロホルモン

Country Status (7)

Country Link
US (2) US9116153B2 (enExample)
EP (2) EP3199951B1 (enExample)
JP (2) JP5785086B2 (enExample)
CN (3) CN102317788A (enExample)
DK (1) DK3199951T3 (enExample)
ES (2) ES2645688T3 (enExample)
WO (1) WO2010049179A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10316583A1 (de) * 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
EP2016394A4 (en) 2006-04-04 2013-04-24 Singulex Inc METHOD AND COMPOSITIONS FOR HIGHLY SENSITIVE ANALYSIS OF MARKERS AND DETECTION OF MOLECULES
DE102006060112A1 (de) * 2006-12-20 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
AU2010259022B2 (en) 2009-06-08 2016-05-12 Singulex, Inc. Highly sensitive biomarker panels
US20130149386A1 (en) * 2011-12-07 2013-06-13 Region Nordjylland Cd36 as biomarker for steatosis
US20130338027A1 (en) * 2012-06-15 2013-12-19 Nuclea Biotechnologies, Inc. Predictive Markers For Cancer and Metabolic Syndrome
JP6196034B2 (ja) 2012-12-20 2017-09-13 ライオン株式会社 高血糖リスク判定用マーカーペプチドおよびその用途
CN103266089A (zh) * 2013-05-09 2013-08-28 南京医科大学第一附属医院 抗人和肽素单克隆抗体mcco1及其应用
US20160097781A1 (en) * 2014-10-01 2016-04-07 Sphingotec Gmbh Method for stratifying a female subject for hormone replacement therapy
CA3134929A1 (en) * 2019-03-28 2020-10-01 Lundoch Diagnostics AB Use of follistatin in type 2 diabetes risk prediction
CN113238063A (zh) * 2021-05-31 2021-08-10 迈克生物股份有限公司 Gdf15评估代谢综合征患者进展为心血管疾病的应用
CN113248590B (zh) * 2021-06-24 2021-09-10 天津奇云诺德生物医学有限公司 一种NT-proBNP蛋白抗原决定簇多肽及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606016D0 (en) * 1996-03-22 1996-05-22 Smithkline Beecham Plc Novel use
DE60335387D1 (de) * 2002-07-16 2011-01-27 Woomera Therapeutics Inc Zusammensetzungen und deren verwendungen zur identifizierung und zum targetting von provasopressinexprimierenden krebszellen
EP1673465A4 (en) * 2003-09-29 2008-04-30 Biosite Inc PROCESS AND COMPOSITIONS FOR SEPSIS DIAGNOSIS
EP1628136A1 (en) * 2004-08-19 2006-02-22 B.R.A.H.M.S. Aktiengesellschaft Method of diagnosis of disease using copeptin
US20070218519A1 (en) * 2005-10-11 2007-09-20 Tethys Bioscience, Inc. Diabetes-associated markers and methods of use thereof
JP5855332B2 (ja) * 2006-10-18 2016-02-09 アクセラ インコーポレーテッド 広い濃度範囲にわたる複数アナライトの光回折による測定
JP5320294B2 (ja) * 2006-10-26 2013-10-23 ベー.エル.アー.ハー.エム.エス ゲーエムベーハー プロバソプレシンまたはその断片および部分ペプチド、特にコペプチンまたはニューロフィジンiiを使用する、急性冠動脈症候群についてのリスク層化
WO2008128352A1 (en) * 2007-04-19 2008-10-30 Axela, Inc. Methods and compositions for signal amplification

Similar Documents

Publication Publication Date Title
JP2012507020A5 (enExample)
Khan et al. N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients
JP5718981B2 (ja) 原発性慢性腎臓疾患の進行についての予後バイオマーカー
DK2823314T3 (en) Predicting outcome in patients with chronic obstructive pulmonary disease
Emdin et al. Comparison of brain natriuretic peptide (BNP) and amino-terminal ProBNP for early diagnosis of heart failure
JP5711131B2 (ja) 最初の有害事象の予測のためのバイオマーカー
JP5945063B2 (ja) 慢性心不全が疑われる患者における有害事象の予後
JP6055005B2 (ja) 糖尿病の予測バイオマーカーとしてのアルギニンバソプレシンプロホルモン
CN103884841A (zh) 利用新颖标志物CT-proADM进行诊断和危险分层
EP1888765A2 (en) Methods and compositions for the diagnosis of venous thromboembolic disease
JP2010520442A (ja) Nyhai患者についてのナトリウム利尿ペプチドによる心機能不全の診断および危険性層化
WO2010077654A1 (en) Combined natriuretic peptide assays
Chen et al. Increased serum 2-oxoglutarate associated with high myocardial energy expenditure and poor prognosis in chronic heart failure patients
Breidthardt et al. The novel marker LTBP2 predicts all-cause and pulmonary death in patients with acute dyspnoea
RU2011103526A (ru) Диагностирование хронической обструктивной болезни легких (хобл)
Pervez et al. Prognostic and diagnostic significance of mid-regional pro-atrial natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 Study
Chien et al. Comparison of Abbott AxSYM and Roche Elecsys 2010 for measurement of BNP and NT-proBNP
Mok et al. Premorbid levels of high-sensitivity cardiac troponin T and natriuretic peptide and prognosis after incident myocardial infarction
Choi et al. The clinical significance of serum N-terminal pro-brain natriuretic peptide in systemic sclerosis patients
WO2024119898A1 (zh) 血清可溶性st2在制备预测主动脉夹层患者预后产品中的应用及相关预测装置
CN101600967B (zh) 和肽素或后叶激素运载蛋白ii在制备急性冠状动脉综合征危险性分级试剂盒的用途
US20160299154A1 (en) Biomarker for cardiac disorders
EP3918343B1 (en) Method to predict treatment response in patients with nocturnal enuresis
Feola et al. Comparison between immunoradiometric and fluorimetric brain natriuretic peptide determination in patients with congestive heart failure
van Hateren et al. Copyright (C) 2011 by The American Association for Clinical Chemistry